Behavior
Conduct extensive pain, sensory, motor, and cognitive behavioral testing.
MD Biosciences provides a comprehensive suite of well-characterized Experimental Autoimmune Encephalomyelitis (EAE) rodent models to advance inflammation and multiple sclerosis research. Our MOG, PLP, and MBP EAE models deliver actionable insights for therapeutic development, supported by advanced assessments that enhance translational relevance.
The myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) model is widely used to study chronic, progressive forms of multiple sclerosis. MOG, a key protein in myelin, triggers immune responses that lead to demyelination, motor impairment, and paralysis in rodent models. This model closely mimics many aspects of human multiple sclerosis, offering valuable insights into disease progression.
The proteolipid protein (PLP)-induced EAE model is designed to study remitting and relapsing forms of demyelinating disease. PLP, a major structural component of myelin, triggers immune responses and encephalitis in specific mouse strains, providing insights into relapsing MS pathology.
The myelin basic protein (MBP)-induced EAE model is a valuable tool for studying acute relapses in multiple sclerosis. A single dose of MBP induces transient hind paw paralysis, mimicking early-stage MS-like episodes. Histological analysis highlights mononuclear cell infiltration and foci formation in the cervical spinal cord, without demyelination, making this model ideal for investigating early inflammatory events in multiple sclerosis.
The figure shows motor evoked potentials in naïve, mild, and severe EAE models. Electrophysiological characterization shows how early EAE causes desynchronized neural activity and hypersensitivity, leading to motor and sensory loss in later stages.
MD Biosciences offers comprehensive in vivo measures and endpoint assessments, delivering robust data packages to support critical research decisions in the evolving landscape of drug development and biomedical research.
Conduct extensive pain, sensory, motor, and cognitive behavioral testing.
Explore inflammatory and pain biomarkers in disease-specific tissues.
Characterize tissue and cellular changes in disease, pain, and neurodegeneration.
Measure motor and sensory evoked potentials to assess disease progression and pain.
MD Biosciences is your dedicated partner in drug development, offering tailored study designs, translational models, and comprehensive endpoint assessments. With short lead times, competitive pricing, and deep scientific expertise, we help move your pipeline forward efficiently.